Kim JM - Search Results

1

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, Guthrie V, McCoon P, Li W, Wu S, Zhang Q, Rebelatto MC, Kim JW. Oh DY, et al. Among authors: kim jm, kim ty, kim jw. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9. Lancet Gastroenterol Hepatol. 2022. PMID: 35278356 Clinical Trial.

2

Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments.

Kim JM, Kim JH, Kim SJ, Park KD, Shin HY, Ahn HS, Yu YS. Kim JM, et al. Among authors: kim sj, kim jh. Korean J Ophthalmol. 2010 Dec;24(6):347-52. doi: 10.3341/kjo.2010.24.6.347. Epub 2010 Nov 23. Korean J Ophthalmol. 2010. PMID: 21165233 Free PMC article.

3

The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.

Kim JW, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, Jin MH, Oh KS, Kim JM, Kim TY, Oh DY. Kim JW, et al. Among authors: kim jm, kim ty. Liver Int. 2021 Feb;41(2):388-395. doi: 10.1111/liv.14636. Liver Int. 2021. PMID: 32780918

4

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients.

Park W, Bang JH, Nam AR, Jin MH, Seo H, Kim JM, Oh KS, Kim TY, Oh DY. Park W, et al. Among authors: kim jm, kim ty. Cancer Res Treat. 2021 Jan;53(1):199-206. doi: 10.4143/crt.2020.497. Epub 2020 Oct 6. Cancer Res Treat. 2021. PMID: 33070562 Free PMC article.

5

WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.

Jin MH, Nam AR, Bang JH, Oh KS, Seo HR, Kim JM, Yoon J, Kim TY, Oh DY. Jin MH, et al. Among authors: kim jm, kim ty. Gastric Cancer. 2021 Sep;24(5):1003-1020. doi: 10.1007/s10120-021-01176-7. Epub 2021 Mar 16. Gastric Cancer. 2021. PMID: 33723720

6

ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.

Nam AR, Yoon J, Jin MH, Bang JH, Oh KS, Seo HR, Kim JM, Kim TY, Oh DY. Nam AR, et al. Among authors: kim jm, kim ty. Cancer Lett. 2021 Sep 28;516:38-47. doi: 10.1016/j.canlet.2021.05.029. Epub 2021 May 31. Cancer Lett. 2021. PMID: 34082024 Clinical Trial.

7

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.

Seo HR, Nam AR, Bang JH, Oh KS, Kim JM, Yoon J, Kim TY, Oh DY. Seo HR, et al. Among authors: kim jm, kim ty. Cancer Res Treat. 2022 Apr;54(2):541-553. doi: 10.4143/crt.2021.473. Epub 2021 Aug 6. Cancer Res Treat. 2022. PMID: 34352995 Free PMC article.

8

A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers.

Oh KS, Nam AR, Bang JH, Seo HR, Kim JM, Yoon J, Kim TY, Oh DY. Oh KS, et al. Among authors: kim jm, kim ty. Oncogene. 2022 Aug;41(32):3939-3952. doi: 10.1038/s41388-022-02384-w. Epub 2022 Jul 7. Oncogene. 2022. PMID: 35798878

9

Intralesional Electrocoagulation With Insulated Microneedle for the Treatment of Periorbital Syringomas: A Retrospective Analysis.

Ahn GR, Jeong GJ, Kim JM, Hong JY, Li K, Lee CK, Kim BJ. Ahn GR, et al. Among authors: kim jm, kim bj. Aesthet Surg J. 2021 Mar 12;41(4):490-498. doi: 10.1093/asj/sjz288. Aesthet Surg J. 2021. PMID: 31630165

10

Modified argon laser therapy for benign tumor of the eyelid.

Han J, Lee SH, Choi CY, Khoramnia R, Kim J, Shin HJ. Han J, et al. BMC Ophthalmol. 2022 Sep 24;22(1):383. doi: 10.1186/s12886-022-02601-w. BMC Ophthalmol. 2022. PMID: 36153503 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,037 results

Search Page

Filters